<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Biotech on Neputer Blog</title><link>https://blog.neputer.com/tags/biotech/</link><description>Recent content in Biotech on Neputer Blog</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Fri, 25 Sep 2026 13:36:34 +0545</lastBuildDate><atom:link href="https://blog.neputer.com/tags/biotech/index.xml" rel="self" type="application/rss+xml"/><item><title>AI Discovers a New CRISPR-Like Gene Editor in 21 Hours — The Lab Is Now Digital</title><link>https://blog.neputer.com/news/2026-09-25-ai-discovers-a-new-crispr-like-gene-editor-in-21-hours-/</link><pubDate>Fri, 25 Sep 2026 13:36:34 +0545</pubDate><guid>https://blog.neputer.com/news/2026-09-25-ai-discovers-a-new-crispr-like-gene-editor-in-21-hours-/</guid><description>Anthropic deployed 950 Claude agents to autonomously screen bacteriophage DNA and discover a novel CRISPR-like enzyme system.</description></item><item><title>37,000 AI Scientists Go to Work: Virtual Biotech Company Predicts Drug Trial Success</title><link>https://blog.neputer.com/news/2026-09-18-37000-ai-scientists-go-to-work-virtual-biotech-company-/</link><pubDate>Fri, 18 Sep 2026 13:10:23 +0545</pubDate><guid>https://blog.neputer.com/news/2026-09-18-37000-ai-scientists-go-to-work-virtual-biotech-company-/</guid><description>Stanford researchers create a virtual biotech firm of 37,000 AI agents that independently designed a lung cancer therapy later validated in trials.</description></item><item><title>Claude Cracks Protein Design—14/15 Targets, Human Experts Outclassed</title><link>https://blog.neputer.com/news/2026-08-21-claude-cracks-protein-design1415-targets-human-experts-/</link><pubDate>Fri, 21 Aug 2026 09:01:51 +0545</pubDate><guid>https://blog.neputer.com/news/2026-08-21-claude-cracks-protein-design1415-targets-human-experts-/</guid><description>Anthropic&amp;#39;s Claude autonomously designed novel proteins for 14 of 15 targets, achieving 26.8% success rate—double the industry norm.</description></item></channel></rss>